144 related articles for article (PubMed ID: 38151842)
1. Breaking Barriers: Current Advances and Future Directions in Mpox Therapy.
Shah BM; Modi P
Curr Drug Targets; 2024; 25(1):62-76. PubMed ID: 38151842
[TBL] [Abstract][Full Text] [Related]
2. Clinical considerations on monkeypox antiviral medications: An overview.
Pourkarim F; Entezari-Maleki T
Pharmacol Res Perspect; 2024 Feb; 12(1):e01164. PubMed ID: 38149674
[TBL] [Abstract][Full Text] [Related]
3. The discovery of novel antivirals for the treatment of mpox: is drug repurposing the answer?
Ezat AA; Abduljalil JM; Elghareib AM; Samir A; Elfiky AA
Expert Opin Drug Discov; 2023 May; 18(5):551-561. PubMed ID: 37032577
[TBL] [Abstract][Full Text] [Related]
4. Repurposing of the antibiotic nitroxoline for the treatment of mpox.
Bojkova D; Zöller N; Tietgen M; Steinhorst K; Bechtel M; Rothenburger T; Kandler JD; Schneider J; Corman VM; Ciesek S; Rabenau HF; Wass MN; Kippenberger S; Göttig S; Michaelis M; Cinatl J
J Med Virol; 2023 Mar; 95(3):e28652. PubMed ID: 36897017
[TBL] [Abstract][Full Text] [Related]
5. Overview of the regulatory approval of tecovirimat intravenous formulation for treatment of smallpox: potential impact on smallpox outbreak response capabilities, and future tecovirimat development potential.
Russo AT; Grosenbach DW; Honeychurch KM; Long PG; Hruby DE
Expert Rev Anti Infect Ther; 2023 Mar; 21(3):235-242. PubMed ID: 36728515
[TBL] [Abstract][Full Text] [Related]
6. Therapeutics for treating mpox in humans.
Fox T; Gould S; Princy N; Rowland T; Lutje V; Kuehn R
Cochrane Database Syst Rev; 2023 Mar; 3(3):CD015769. PubMed ID: 36916727
[TBL] [Abstract][Full Text] [Related]
7. Trifluridine for treatment of mpox infection in drug combinations in ophthalmic cell models.
Cinatl J; Bechtel M; Reus P; Ott M; Rothweiler F; Michaelis M; Ciesek S; Bojkova D
J Med Virol; 2024 Jan; 96(1):e29354. PubMed ID: 38180134
[TBL] [Abstract][Full Text] [Related]
8. Emerging pharmacological strategies for treating and preventing mpox.
Grosenbach DW; Russo AT; Blum ED; Hruby DE
Expert Rev Clin Pharmacol; 2023; 16(9):843-854. PubMed ID: 37592723
[TBL] [Abstract][Full Text] [Related]
9. Recent Advances in the Prevention and Management of Monkeypox Viral Infection in Humans.
Gujjar P; Chaudhay R; Verma I; Bansal N; Gupta S; Bansal S
Curr Drug Targets; 2023; 24(13):1032-1045. PubMed ID: 37842888
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological treatment and vaccines in monkeypox virus: a narrative review and bibliometric analysis.
Shamim MA; Satapathy P; Padhi BK; Veeramachaneni SD; Akhtar N; Pradhan A; Agrawal A; Dwivedi P; Mohanty A; Pradhan KB; Kabir R; Rabaan AA; Alotaibi J; Al Ismail ZA; Alsoliabi ZA; Al Fraij A; Sah R; Rodriguez-Morales AJ
Front Pharmacol; 2023; 14():1149909. PubMed ID: 37214444
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Mpox with Suspected Tecovirimat Resistance in Immunocompromised Patient, United States, 2022.
Contag CA; Mische L; Fong I; Karan A; Vaidya A; McCormick DW; Bower W; Hacker JK; Johnson K; SanJuan P; Crebbin L; Temmins C; Sahni H; Bogler Y; Cooper JD; Narasimhan S
Emerg Infect Dis; 2023 Dec; 29(12):2520-2523. PubMed ID: 37856215
[TBL] [Abstract][Full Text] [Related]
12. Drug repurposing for Mpox: Discovery of small molecules as potential inhibitors against DNA-dependent RNA polymerase using molecular modeling approach.
Dutt M; Kumar A; Rout M; Dehury B; Martinez G; Ndishimye P; Kelvin AA; Kelvin DJ
J Cell Biochem; 2023 May; 124(5):701-715. PubMed ID: 36946432
[TBL] [Abstract][Full Text] [Related]
13. Potential therapeutic targets for Mpox: the evidence to date.
Byrareddy SN; Sharma K; Sachdev S; Reddy AS; Acharya A; Klaustermeier KM; Lorson CL; Singh K
Expert Opin Ther Targets; 2023; 27(6):419-431. PubMed ID: 37368464
[TBL] [Abstract][Full Text] [Related]
14. Update on monkeypox virus infection: Focusing current treatment and prevention approaches.
Dhapola R; Kumari S; Sharma P; KumarKushawaha P; HariKrishnaReddy D
Fundam Clin Pharmacol; 2024 Jun; 38(3):465-478. PubMed ID: 38226405
[TBL] [Abstract][Full Text] [Related]
15. Identification of core therapeutic targets for Monkeypox virus and repurposing potential of drugs against them: An in silico approach.
Sahu A; Gaur M; Mahanandia NC; Subudhi E; Swain RP; Subudhi BB
Comput Biol Med; 2023 Jul; 161():106971. PubMed ID: 37211001
[TBL] [Abstract][Full Text] [Related]
16. Managing Monkeypox Virus Infections: A Contemporary Review.
Asadi Noghabi F; G Rizk J; Makkar D; Roozbeh N; Ghelichpour S; Zarei A
Iran J Med Sci; 2024 Jan; 49(1):1-9. PubMed ID: 38322157
[TBL] [Abstract][Full Text] [Related]
17. VP37 Protein Inhibitors for Mpox Treatment: Highlights on Recent Advances, Patent Literature, and Future Directions.
Hudu SA; Alshrari AS; Al Qtaitat A; Imran M
Biomedicines; 2023 Apr; 11(4):. PubMed ID: 37189724
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and viral dynamics of tecovirimat in patients with MPOX: A multicenter open-label, double-arm trial in Japan.
Akiyama Y; Morioka S; Tsuzuki S; Yoshikawa T; Yamato M; Nakamura H; Shimojima M; Takakusaki M; Saito S; Takahashi K; Sanada M; Komatsubara M; Takebuchi K; Yamaguchi E; Suzuki T; Shimokawa K; Kurosu T; Kawahara M; Oishi K; Ebihara H; Ohmagari N
J Infect Chemother; 2024 Jun; 30(6):488-493. PubMed ID: 38042298
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic strategies for human poxvirus infections: Monkeypox (mpox), smallpox, molluscipox, and orf.
De Clercq E; Jiang Y; Li G
Travel Med Infect Dis; 2023; 52():102528. PubMed ID: 36539022
[TBL] [Abstract][Full Text] [Related]
20. Repurposing Amphotericin B and Its Liposomal Formulation for the Treatment of Human Mpox.
Peruzzu D; Fecchi K; Venturi G; Gagliardi MC
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
